Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.

Comparing FLT3-ITD MRD before and after conditioning, there was no difference between myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) in eradication or reduction of FLT3-ITD MRD.

比较了移植前化疗前后FLT3-ITD MRD的情况，发现髓系消融性化疗（MAC）和减低强度化疗（RIC）在消除或减少FLT3-ITD MRD方面没有差异。

For participants who were FLT3-ITD MRD negative before HCT, there was no difference in the cumulative incidenceof relapse during follow-up between those receiving MAC vs RIC.

对于造血干细胞移植（HCT）前FLT3-ITD MRD阴性的参与者，在随访期间接受MAC与RIC的累积复发发生率没有差异。

NPM1 comutation was associated with the largest magnitude of relapse-free survival benefit from post-HCT gilteritinib, and in these participants, post-HCT gilteritinib in the setting of RIC appeared to be as effective as MAC at preventing relapse.

NPM1共突变与接受造血干细胞移植（HCT）后吉列替尼治疗的无复发生存（relapse-free survival）受益最大，而在这些参与者中，RIC背景下的HCT后吉列替尼治疗在预防复发方面似乎与MAC同样有效。

MAC appeared superior to RIC in preventing relapse only in participants who were NPM1 wild type at diagnosis and FLT3-ITD MRD positive before HCT.

在诊断时NPM1野生型且在造血干细胞移植（HCT）前FLT3-ITD MRD阳性的参与者中，MAC在预防复发方面似乎优于RIC。

Our findings suggest that only a subset of patients with FLT3-ITD AML undergoing HCT may benefit from MAC and that, similar to AML therapy before HCT, the intensity of the HCT regimen should be adapted according to the molecular features of the disease.

我们的发现表明，只有接受HCT的FLT3-ITD AML患者的一部分可能从MAC中受益，并且，与HCT前的AML治疗类似，HCT方案的强度应根据疾病的分子特征进行调整。

This trial was registered at www.clinicaltrials.gov as #NCT02997202.

该试验已在www.clinicaltrials.gov上注册，注册号为#NCT02997202。